Elusys Therapeutics Receives First Delivery Order from U.S. Government for ANTHIM® (Obiltoxaximab) for Treatment of Inhalational Anthrax

Media Center PRESS RELEASE 2015 ELUSYS THERAPEUTICS RECEIVES FIRST DELIVERY ORDER FROM U.S. GOVERNMENT FOR ANTHIM® (OBILTOXAXIMAB) FOR TREATMENT OF INHALATIONAL ANTHRAX PINE BROOK, NJ, NOVEMBER 12, 2015 – Elusys Therapeutics, Inc. (Elusys) today announced it has been awarded its first delivery order under a procurement contract for Anthim (obiltoxaximab), an investigational agent for the treatment […]

Elusys Awarded Additional $16 Million Under Existing U.S. Government Contract to Complete Development of Lyophilized Form of ANTHIM® (Obiltoxaximab) for Treatment of Inhalational Anthrax

Media Center PRESS RELEASE 2015 ELUSYS AWARDED ADDITIONAL $16 MILLION UNDER EXISTING U.S. GOVERNMENT CONTRACT TO COMPLETE DEVELOPMENT OF LYOPHILIZED FORM OF ANTHIM®(OBILTOXAXIMAB) FOR TREATMENT OF INHALATIONAL ANTHRAX Lyophilized Anthim has potential to improve shelf life and operational flexibility U.S. FDA is currently reviewing Elusys’ BLA for the liquid form of Anthim PINE BROOK, NJ, […]

U.S. Food and Drug Administration Accepts Biologics License Application for ANTHIM (Obiltoxaximab)

Media Center PRESS RELEASE 2015 U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS BIOLOGICS LICENSE APPLICATION FOR ANTHIM (OBILTOXAXIMAB) PINE BROOK, NJ, June 1, 2015 – Elusys Therapeutics, Inc. (Elusys) today announced the U.S. Food and Drug Administration (FDA) has accepted for filing and review its Biologics License Application (BLA) for Anthim® (obiltoxaximab) for the treatment and prevention […]

Elusys Reports Efficacy of its Anthrax Anti-Toxin In Post-Exposure Prophylaxis In Animal Studies

Media Center PRESS RELEASE 2015 ELUSYS REPORTS EFFICACY OF ITS ANTHRAX ANTI-TOXIN IN POST-EXPOSURE PROPHYLAXIS IN ANIMAL STUDIES Company presents data from research studies at ASM Biodefense conference this week PINE BROOK, NJ, February 12, 2015 – Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data demonstrating that […]